Browse the latest reports in the Healthcare industry below
Healthcare Reports
The healthcare and pharma industries face many challenges - drug development, shifting demographics and evolving legislation to name a few. Our reports provide unparalleled analysis of market trends and their implications so you can navigate, understand and capitalize on the opportunities in the global healthcare and pharmaceutical markets. Our reports provide an independent, comprehensive range of analysis, forecasts and data to help you:
- Evaluate market opportunities and risks
- Monitor competitors and customers
- Assess the impact of a changing regulations
- Plan and forecast budgets
- Stay up to date with recent industry developments and market trends
-
Ultrasound Systems Market to 2019 - Technological Advancements, Wide Applications and Device Portability to Drive Future Growth more info
GBI Research’s “Ultrasound Systems Market to 2019 - Technological Advancements, Wide Applications and Device Portability to Drive Future Growth” report examines the market, competitive landscape, and trends for the following two ultrasound systems market segments: color doppler ultrasound systems and B/W ultrasound systems. The report provides comprehensive information on the key trends affecting these segments, and key analytical content related to market dynamics. The report also reviews the competitive landscape and provides a detailed analysis of the pipeline products for each segment, as well as details of important Mergers and Acquisitions (M&A) deals. The report has been compiled using data and information sourced from proprietary databases, primary and secondary research and in-house analysis carried out by GBI Research’s team of industry experts.By: GBI Research, Published: May-2013, Product code: GBIME0083MR
PAGES:
80
TABLES:
47
FIGURES & CHARTS:
39
$3,500.00 -
Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players more info
GBI Research, the leading business intelligence provider, has released its latest research “Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players”. Japan’s pharmaceutical industry is the second largest in the world, worth $89 billion in 2011 or 10% of the world market. The industry grew from $62.8 billion in 2005 to its current value at a Compound Annual Growth Rate (CAGR) of 5.1%.By: GBI Research, Published: Apr-2013, Product code: GBIHC289MR
PAGES:
97
TABLES:
15
FIGURES & CHARTS:
57
$3,500.00 -
PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry more info
The PharmaSphere, Early-Stage Technology Transfer Collaborations Report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 pharma-academic alliances from 2012–2013. GlobalData’s Industry Dynamics team of analysts discusses the significant macro-environment drivers which are leading to an increase in research partnerships with academic research institutions on behalf of pharmaceutical companies. We also discuss the unsustainability of the current drug research model, and the industry’s attempts at moving toward an open R&D ecosystem.By: GlobalData, Published: Apr-2013, Product code: GDHC003PSR
PAGES:
85
TABLES:
27
FIGURES & CHARTS:
7
$2,995.00 -
EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2022 more info
Idiopathic pulmonary fibrosis (IPF) is a chronic, fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults and is associated with a histologic and/or radiologic pattern of usual interstitial pneumonia (NHLBI, 2011; Raghu et al., 2011). As a fatal disease that falls under the umbrella of interstitial lung disease of unknown cause, IPF is limited to the lungs and manifests with irreversible and variable scarring, stiffening, and thickening of the lung tissues that leads to progressively worsening of pulmonary function (NHLBI, 2011; Raghu et al. 2011). IPF is the most common form of idiopathic interstitial pneumonia and also has the worst prognosis, with only three to five years of median survival (Olson and Swigris, 2012). Respiratory failure accounts for over 80% of IPF fatalities (Raghu et al., 2006). IPF is more common in men, and its prevalence typically increases with advancing age.By: GlobalData, Published: Apr-2013, Product code: GDHCER020
PAGES:
41
TABLES:
8
FIGURES & CHARTS:
6
$3,995.00 -
Bronchospasm Global Clinical Trials Review, H1, 2013 more info
GlobalData's clinical trial report, “Bronchospasm Global Clinical Trials Review, H1, 2013" provides data on the Bronchospasm clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bronchospasm. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bronchospasm. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.By: GlobalData, Published: Apr-2013, Product code: GDHC1646CTIDB
PAGES:
71
TABLES:
39
FIGURES & CHARTS:
15
$2,500.00 -
Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals more info
GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.By: GlobalData, Published: Apr-2013, Product code: GDPH0385MD
PAGES:
68
TABLES:
44
FIGURES & CHARTS:
39
$1,000.00 -
Tardive Dyskinesia Global Clinical Trials Review, H1, 2013 more info
GlobalData's clinical trial report, “Tardive Dyskinesia Global Clinical Trials Review, H1, 2013" provides data on the Tardive Dyskinesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Tardive Dyskinesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Tardive Dyskinesia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.By: GlobalData, Published: Apr-2013, Product code: GDHC1645CTIDB
PAGES:
83
TABLES:
38
FIGURES & CHARTS:
20
$2,500.00 -
Strategic Overview of Global Preventable Vaccine Market 2012-2016 more info
TechNavio's analysts forecast the Strategic Overview of Global Preventable Vaccine Market to grow at a CAGR of 8.99 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in demand for vaccination. The Strategic Overview of Global Preventable Vaccine market has also been witnessing the trend of increase in market consolidation. However, the emergence of regional players could pose a challenge to the growth of this market.
By: Technavio, Published: Apr-2013, Product code: IRTNTR2076
PAGES:
111
TABLES:
0
FIGURES & CHARTS:
0
$3,000.00 -
EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022 more info
Chronic Myeloid Leukemia (CML) is a rare cancer of the white blood cells characterized by increased and unregulated growth of myeloid cells originating in the bone marrow that invade the blood and potentially other organs, depending on the phase of the cancer (ACS, 2012; NLM, 2012). Based on clinical characteristics and laboratory findings, CML is divided into three phases: chronic, accelerated, and blast crisis; most people with CML are diagnosed at the chronic phase (NLM, 2012). The diagnosis of CML is based on the presence of the Philadelphia (Ph) chromosome, which is the product of a distinctive cytogenetic abnormality where the BCR gene on chromosome 22 becomes fused to the ABL gene on chromosome 9, generating the BCR-ABL fusion oncogene, which produces the BCR-ABL protein and triggers CML. The Ph chromosome is present in 95% of CML patients (Jabbour and Kantarjian, 2012; Sawyers, 1999).By: GlobalData, Published: Apr-2013, Product code: GDHCER014
PAGES:
43
TABLES:
9
FIGURES & CHARTS:
7
$3,995.00 -
Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2013 more info
GlobalData's clinical trial report, “Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2013" provides data on the Lennox-Gastaut Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lennox-Gastaut Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lennox-Gastaut Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.By: GlobalData, Published: Apr-2013, Product code: GDHC1641CTIDB
PAGES:
79
TABLES:
32
FIGURES & CHARTS:
16
$2,500.00
Refine Your Search
- Industry
- Price
- Publisher
- Region
- Report Type
Why buy direct from us?
Huge Selection
Industry Report Store has one of the largest databases of market research reports.
Instant Delivery
Most reports are available for immediate download upon purchase and full payment.
Best Price Guarantee
As we publish many of the reports ourselves, we set the prices and can offer special discounts.
All transactions are secured with SSL Security. 
Loading...